

Kidswell Bio (TYO: 4584)

Received approval for the fourth BS product (GBS-010).
2Q FY2023 financial results were in line with the plan.

◇ Summary of 2Q FY2023 Financial Results

Kidswell Bio's 2Q FY2023 financial results came out in line with the initial forecasts. Sales were 580 million yen (-47.9% YoY), operating loss was 720 million yen (vs. an operating income of 11 million yen in the same quarter of FY2022), and net loss was 780 million yen (vs. a net loss of 0.04 billion yen last year). The company believes it can meet its full-year forecasts because sales contributions from biosimilar (BS) products, including GBS-007, will be concentrated in the second half. As for the company's other BS products, GBS-010 (Pegfilgrastim BS), the fourth BS product, received approval in September and is expected to be launched this year. In the cell therapy business (regenerative medicine), the company completed enrollment of the first patient in a Nagoya University-led clinical research for children with cerebral palsy. Progress is also being made in the clinical development of SHED (Stem cells from Human Exfoliated Deciduous teeth).

◇ Stock Price Trends:

The company's stock price positively reacted to the announcement of the approval of the fourth BS product on September 26, rising 30% from the previous day, but has since returned to its recent downtrend. Although the BS business is expanding, as described below, the profitability of BS is below the forecast due to the weaker yen and higher import costs due to inflation overseas and because the company expects further investment related to SHED. The stock price is at an extremely low level, and we would like to keep an eye on the earnings trend, particularly for BS, progress in the pipeline for regenerative medicine and other products, as well as where related up-front payments and milestone revenues could go.

◇ 2Q FY2023 Results: Sales down due to a bias toward the second half of the fiscal year

In 2Q FY2023, the company posted **sales of 581 million yen, down 47.9% YoY, an operating loss of 719 million yen (vs. operating income of 11 million yen in 2Q FY2022), and a net loss of 780 million yen (vs. net loss of 42 million yen last year).**

YoY sales declined due to the absence of the one-time revenue from the completion of the master cell bank in the same period of the previous year, and, as noted in the last report, the timing of the BS shipments in this 1Q led to a decline in sales. In addition, the company's 2Q gross profit declined 66.9% YoY due to higher import costs by the weak yen and inflation overseas (the company's bulk pharmaceuticals for BS are procured from overseas).

The company continued to invest in R&D for regenerative medicine, centering on SHED and posted 546 million yen in R&D expenses in 2Q, which doubled YoY, and a 38.8% YoY increase in SG&A expenses. As a result, the company registered an operating loss of 719 million yen, down from a profit of 11 million yen in 2Q FY2022. Non-operating expenses included 8 million yen in interest paid on a bank loan. The company posted a net loss of 780 million yen, compared with a net loss of 42 million yen in 1Q FY2022 (see next page, top chart).


2Q results update

Healthcare

As of November 14, 2023

Share price(11/13)	¥132
52 weeks high/low	¥352/126
Avg Vol (3 month)	775.8 thou shrs
Market Cap	¥4.7 bn
Enterprise Value	¥5.8 bn
PER (24/3 CE)	- X
PBR (23/3 act)	5.30 X
Dividend Yield (24/3 CE)	- %
ROE (TTM)	-100.5 %
Operating margin (TTM)	-57.2 %
Beta (5Y Monthly)	N/A
Shares Outstanding	35.837 mn shrs
Listed market	TSE Growth

Share price performance



% of	1 mo.	3 mo.	12 mo.
Share prices	-8.3%	-25.4%	-53.8%
Relative share price	-9.4%	-26.5%	-61.3%

Points of interest

Drug discovery venture originated from Hokkaido University, with a leading track record in BS. 4th BS product was approved. Cell therapy (regenerative medicine) based on SHED is now in the clinical stage. Plans are underway for second-generation SHED with a view to international expansion.

This report (Company note) has been prepared on behalf of Kidswell Bio. For more information, please refer to the Disclaimer on the last page.

JPY, mn, %	Net sales	YoY %	Oper. profit	YoY %	Ord. profit	YoY %	Profit ATOP	YoY %	EPS (¥)
2020/3	1,077	-	-1,161	-	-1,187	-	-7,316	-	-264.65
2021/3	996	-7.5	-969	-	-991	-	-1,001	-	-34.79
2022/3	1,569	62.3	-651	-	-968	-	-535	-	-17.86
2023/3*	2,776	76.9	-550	-	-624	-	-657	-	-20.77
2024/3 (CE)	3,500	26.1	-1,500	-	-1,550	-	-1,550	-	-45.23
2023/3 2Q*	1,116	-	11	-	-42	-	-42	-	-1.36
2024/3 2Q	581	-47.9	-719	-	-744	-	-780	-	-24.10

* FY2019 - FY2021 on a consolidated basis; FY2022 onwards on a non-consolidated basis.

2Q FY2023 Results (PL)

Unit : thousands yen

Subject	Results for 2Q FY2022	FY2023 ending March 31, 2024		Forecast	Progress rate
		Results for 2Q	Year-on-year ratio		
Gross sales	1,116,111	581,870	52%	3,500,000	17%
Cost of goods sold	420,954	351,901	84%		
Gross profit	695,156	229,968	33%		
Selling, general and administrative expenses	684,018	949,627	139%		
R&D expenses	251,787	546,693	217%	1,600,000	34%
Other expenses	432,230	402,933	93%		
Operating loss	11,137	-719,658	--	-1,500,000	--
Net loss	-42,082	-744,646	--	-1,550,000	--
Net loss for the quarter	-42,687	-780,251	--	-1,550,000	--

Source: Company materials

On the balance sheet, cash and deposits were virtually unchanged from the end of 1Q, but accounts receivable increased by 407 million yen due to an increase in biosimilar sales. In addition, the equity finance announced in July 2023 enabled the manufacturing of biosimilars business to proceed as planned and improved shareholders' equity, increasing total net assets by 306 million yen to 1,075 million yen. As a result, total assets at the end of September 2023 amounted to 3,193 million yen, up 149 million yen from the end of June 2023. The company expects to improve its capital efficiency in the future, mainly by shortening the time to recover manufacturing funds through cooperation and support from its partners.

◆ Biosimilars Business: The fourth product (GBS-010) received approval in September

Pegfilgrastim BS (GBS-010), which the company has been developing with Mochida Pharmaceutical as a development partner, received manufacturing and marketing approval in September 2023 and is expected to go on sale by the end of this year after listing on the NHI drug price list in November. GBS-010 effectively prevents the onset of febrile neutropenic symptoms caused by cancer chemotherapy and was approved as the first BS to be used against the prior product G-LASTA (Kyowa Kirin). Sales of G-LASTA are expected to be around 30 billion yen in 2022 and grow further on a volume basis.

Currently, there are 18 BS products approved in Japan. Of these, 4 products are from the company. For Filgrastim BS (GBS-001), approved in November 2012, and darbepoetin alfa BS (GBS-011), approved in September 2019, the switch in use from the prior product to BS is over 80%. Ranibizumab BS (GBS-007), approved in September 2021, has no BS competitors. Pegfilgrastim BS (GBS-010) also has no competition, and biosame has not yet been launched. Both products are expected to expand their market shares.

This spring, the Ministry of Health, Labor and Welfare (MHLW) set a target of increasing the percentage of the ingredients of BSs that have replaced at least 80% of the predecessor products (by volume) to at least 60% by the end of FY2029 to promote the widespread use of BSs. Of the current 18 components, three have achieved 80% or more, and the company has launched BS for two of them with its partners. Although it will initially take time to spread, as seen in the case of small molecule generics, it is expected to become more widespread in the future, partly due to policy

BS business line-up

GBS-001 Filgrastim BS (Approved in Nov. 2012) Fuji Pharma Co., Ltd.	GBS-011 Darbepoetin alfa BS (Approved in Sept. 2019) Sanwa Kagaku Kenkyusho Co., Ltd.	GBS-007 Ranibizumab BS (Approved in Sept. 2021) Senju Pharmaceutical Co., Ltd.	GBS-010 Pegfilgrastim BS (Approved in Sept. 2023) Mochida Pharmaceutical Co., Ltd.
<ul style="list-style-type: none"> • Biosimilar of G-CSF preparation filgrastim for neutropenia, etc. Alfa Biosimilar 	<ul style="list-style-type: none"> • Biosimilar of continuous Erythropoiesis Stimulating Factor Preparation Darbepoetin alfa 	<ul style="list-style-type: none"> • Biosimilar of anti-VEGF antibody drug ranibizumab • Strong sales and more orders than expected • Received an approval of partial modification of pharmaceutical manufacturing approval for macular edema associated with retinal vein occlusion as additional indication of Ranibizumab BS in Sept. 2023 	<ul style="list-style-type: none"> • Biosimilar of sustained G-CSF preparation pegfilgrastim • No biosimilars have been approved by competitors as of Sept. 2023.

Source: Company materials


support. The company is exploring partnerships with mid-sized pharmaceutical companies and is considering developing a fifth product and beyond.

❖ Cell Therapy Business (Regenerative Medicine): Enrollment of the first patients for Nagoya University-led clinical research completed

The company's cell therapy business has a pipeline of nearly 10 products. The one making the most progress is the clinical research for cerebral palsy conducted with Nagoya University. On October 16, the company announced that the first case in Nagoya University's clinical research for children with cerebral palsy had been enrolled (<https://jrct.niph.go.jp/latest-detail/jRCTb040230042>). The cells to be administered in this clinical study are autologous cells derived from the patient's own deciduous teeth, and a clinical trial to investigate the safety and tolerability of a single dose will be conducted under the leadership of Nagoya University.

In addition, a portion of the PMDA's consultation on SHED derived from allogenic cells has been completed to enter into a corporate clinical trial for children with cerebral palsy. The company will develop manufacturing methods in GMP facilities for the production of investigational drugs.

Progress in SHED Clinical Development



Source: Company materials

◇ FY2023 full-year forecasts: unchanged from the beginning of the fiscal year

As of the end of 2Q FY2023, the company has not changed its forecasts for net sales, operating loss, and net loss for FY2023, which are 3.5 billion yen, 1.5 billion yen, and 1.55 billion yen, respectively. As of 2Q, the sales progress ratio against the full-year estimate was 17%, which is a concern. However, as mentioned above, in addition to the strong sales of Ranibizumab BS (GBS-007), the newly approved Pegfilgrastim BS (GBS-010) will contribute to sales from December, and with BS sales biased toward the second half, the company expects to achieve its full-year forecasts.

◇ Equity financing, IR, etc.....: Investor Concerns

Since July 2023, the company has been raising funds (equivalent to about 3 billion yen) for working capital for its biosimilar business. The company could have borrowed from banks to raise working capital, which is highly certain to generate sales. Still, it has chosen equity financing this time, considering the need to strengthen its equity capital. Since the company will need to raise R&D expenses continuously, further dilution through equity financing concerns investors. However, when explaining the current financing, President Kurebayashi stated that the company has no immediate plans for equity financing. In addition, if the BS business continues to grow (KWB 2.0, the company's medium-term strategic plan, calls for sales of 3.0 billion yen in FY2025, but the company already expects 3.5 billion yen in FY2024), cash flow from this business will support investment in R&D, including SHED, as previously planned.

As noted in our previous report, President Kurebayashi also assumed the position of CCO (Chief Communications Officer) in conjunction with his appointment as CEO. He has extensive experience in the financial sector, including foreign firms, and fully understands the concerns of investors. Since assuming the position of CEO/CCO, President Kurebayashi has also been taking a more active role in investor relations, holding frequent seminars for individual investors, updating IR materials, and making other changes in IR activities. Hopefully, the company will continue to provide detailed explanations to wipe off investors' concerns.

◇ **Thoughts on stock price: Although having positively reacted to the approval of the fourth BS product, the stock price continues to trend downward. Dissolving investors' concerns is the key to share price recovery.**

The company's stock price rose sharply by +30% on September 26 following the announcement of the approval of the fourth BS product but has since returned to its recent downtrend. This is presumably due to investors' concerns that although the biosimilar business is expanding, its profitability is lower than initially planned, affected by the yen depreciation and higher import costs caused by inflationary economies overseas and that the company expects further investment for research and development, including that for SHED. The company plans to continue reducing manufacturing costs, as the yen's near-term depreciation also weighs on profits.

Drug discovery ventures require funds in the billions of yen or more each year for R&D. Although the company expects to generate cash flow from BS, there are concerns that further financing may be required if drug discovery and development accelerates. In addition, investors may also be concerned about how the company's major shareholders could do with their shareholdings. Drug discovery ventures are inherently risky and require a long investment period, so investors must be able to bear such risks. On the other hand, the company's stock price is at a historic low since its IPO and looks demanding. We expect the share price to turn around as the management team addresses these concerns of investors one by one.

Stock price transition (last 6 years)



Financial data

FY (¥mn)	2021/3				2022/3				2023/3				2024/3	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q*	2Q	3Q	4Q	1Q	2Q
[Statements of income]														
Net sales	121	53	547	276	303	438	642	186	610	505	610	1,049	45	535
Cost of sales	5	35	46	34	122	154	183	91	292	128	233	597	0	351
Gross profit	116	19	500	242	182	283	460	94	318	377	377	453	45	184
SG&A expenses	354	463	465	565	491	425	442	580	356	328	524	869	500	449
R&D expenses	138	265	198	363	297	236	237	380	105	146	327	637	312	234
Operating profit (loss)	-238	-445	36	-323	-309	-142	18	-486	-37	49	-146	-415	-455	-264
Non-operating income	0	1	1	1	2	0	0	1	0	2	0	1	2	0
Non-operating expenses	7	5	4	8	6	8	15	7	43	13	5	17	17	10
Ordinary profit (loss)	-244	-450	33	-330	-314	-150	4	-493	-80	39	-151	-431	-470	-274
Extraordinary income							418	0	-	-	-	-	-	-
Extraordinary expenses	0	1	8	0					-	-	-	-	-	35
Profit (loss) before income taxes	-244	-451	26	-331	-314	-148	421	-493	-80	39	-151	-462	-470	-309
Total income taxes	1	0	0	1	0	1	52	-51	0	1	0	0	302	303
Net profit (loss)	-245	-451	25	-330	-314	-149	369	-441	-80	38	-152	-462	-470	-310
[Balance Sheets]														
Current assets	3,573	3,218	3,329	3,346	2,794	3,203	3,722	3,326	4,079	4,035	3,948	3,697	2,847	3,031
Cash equivalents and short-term securities	2,658	2,502	1,830	1,461	874	974	1,253	1,187	1,532	1,874	1,499	1,067	624	622
Non-current assets	379	393	340	588	728	656	178	177	225	224	224	197	197	161
Tangible assets	2	2	2	3	3	2	2	2	1	1	1	1	1	1
Investments and other assets	374	389	336	582	722	651	173	173	220	220	220	193	193	158
Total assets	3,952	3,611	3,670	3,934	3,522	3,859	3,901	3,503	4,304	4,259	4,173	3,894	3,044	3,193
Current liabilities	772	858	925	1,114	823	1,034	1,045	1,129	1,175	651	780	1,055	767	731
Short-term borrowings	25													
Long-term debts to be repaid within one year								75	250	300	400	375	375	425
Non-current liabilities	1,384	1,287	1,231	1,209	1,051	826	718	656	1,485	1,908	1,704	1,605	1,508	1,387
Long-term debt	1,340	1,240	1,200	1,100	900	700	700	625	1,450	1,875	2,275	1,575	1,475	1,350
Long-term borrowing	600	600	600	600	600	600	600	525	1,350	1,275	1,175	1,075	975	850
Convertible bonds	740	640	600	500	300	100	100	100	100			500	500	500
Total liabilities	2,156	2,145	2,156	2,324	1,873	1,860	1,763	1,785	2,661	2,560	2,485	2,661	2,275	2,118
Total net assets	1,796	1,466	1,514	1,610	1,648	1,999	2,138	1,719	1,643	1,699	1,688	1,233	768	1,075
Total shareholders' equity	1,796	1,466	1,514	1,610	1,648	1,999	2,138	1,719	1,444	1,500	1,490	1,037	571	892
Capital	842	892	912	1,032	1,150	1,420	1,420	1,421	1,424	1,433	1,504	1,509	1,511	1,827
Legal capital reserve	10,147	10,197	10,217	10,338	10,456	10,725	10,726	10,727	10,730	10,739	10,810	10,815	10,817	11,132
Retained earnings	-9,322	-9,773	-9,748	-10,079	-10,393	-10,542	-10,173	-10,614	-10,710	-10,672	-10,824	-11,287	-11,757	-12,067
Stock acquisition right	70	82	101	116	134	145	165	185	199	199	197	195	197	182
Total liabilities and net assets	3,952	3,611	3,670	3,934	3,522	3,859	3,901	3,503	4,304	4,259	4,173	3,894	3,044	3,193
[Statements of cash flows]														
Cash flow from operating activities		-104		-1,267		-857		-1,169		-709		-1,421		-877
Loss before income taxes		-695		-999		-462		-533		-42		-		-
Cash flow from investing activities		-5		-22		-		526		-23		-28		-
Expenditure on acquisition of intangible/physical assets		-3		-3		-		-1		-		-		-
Purchase of investment securities		-		-		-		-		-50		-50		-
Sales of investment securities		-		-		-		526		-		-		-
Cash flow from financing activities		579		718		370		369		1,446		1,356		432
Income from the issuance of convertible bond-type bonds with stock acquisition rights										970		970		-
Income from issuance of shares by exercising stock acquisition rights		599		599		-		-		499		499		-
Income from issuance of stock acquisition rights		-		138		370		369		-		34		584
Proceeds from issuance of new shares		4		4		-		-		-		1		22
Net increase in cash and cash equiv.		468		-571		-486		-273		713		-93		-444
Cash and cash equiv. at beginning of period		2,032		2,032		1,461		1,462		1,160		1,160		1,067
Cash and cash equiv. at end of period		2,501		1,461		974		1,187		1,874		1,067		622

Note: Consolidated basis until FY2021; non-consolidated basis from 1Q FY2022. For the statement of cash flows, the figures for 2Q are the cumulative figures for the period from 1Q to 2Q, and the figures for 4Q are the cumulative figures for the period from 1Q to 4Q. Therefore, the opening balance is also the balance at the beginning of each quarter.

Source: Omega Investment from company materials

Financial data

FY (¥mn)	2013/3	2014/3	2015/3	2016/3	2017/3	2018/3	2019/3	2020/3	2021/3	2022/3	2023/3*
[Statements of income]											
Net sales	60	301	321	1,160	1,089	1,059	1,021	1,077	996	1,569	2,776
Cost of sales	15	141	147	500	397	422	412	653	119	550	1,250
Gross profit	45	159	174	660	692	637	609	424	876	1,018	1,525
SG&A expenses	403	671	998	1,480	1,876	1,550	1,414	1,585	1,846	1,937	2,076
R&D expenses	206	412	689	1,075	1,433	1,107	945	898	963	1,150	1,216
Operating loss	-358	-512	-824	-820	-1,184	-913	-806	-1,161	-969	-919	-550
Non-operating income	0	0	34	50	35	11	3	1	2	2	3
Non-operating expenses	16	5	0	15	27	0	14	27	24	36	77
Ordinary loss	-373	-516	-790	-785	-1,176	-903	-816	-1,187	-991	-952	-624
Extraordinary income						0	7	5		418	-
Extraordinary expenses			0		45		45	6,132	8		31
Loss before income taxes	-373	-517	-790	-785	-1,222	-902	-854	-7,314	-999	-533	-656
Total income taxes	3	2	1	1	2	1	1	2	1	1	1
Net loss	-377	-519	-792	-787	-1,224	-904	-856	-7,316	-1,001	-535	-657
[Balance Sheets]											
Current assets	919	1,881	1,092	1,520	3,421	2,692	2,821	3,322	3,346	3,325	3,697
Cash and cash equivalents	887	1,610	599	817	2,379	1,891	2,009	2,032	1,461	1,187	1,067
Non-current assets	3	4	54	173	284	332	329	269	587	177	197
Tangible assets	1	0	0	2	1	1	1	1	3	1	1
Investments and other assets	2	3	53	171	282	330	328	267	581	172	193
Total assets	922	1,886	1,146	1,694	3,706	3,025	3,151	3,592	3,933	3,503	3,894
Current liabilities	24	50	92	1,279	189	404	400	880	1,114	1,128	1,055
Short-term borrowings				810				25		75	375
Non-current liabilities	9	783	783	11	16	16	19	1,223	1,209	656	1,605
Total liabilities	34	833	876	1,290	205	421	420	2,104	2,323	1,784	2,661
Total net assets	888	1,052	270	403	3,500	2,604	2,731	1,487	1,610	1,718	1,233
Total shareholders' equity	888	1,031	249	383	3,472	2,568	2,695	1,451	1,291	1,533	1,037
Capital stock	1,239	1,571	1,576	2,037	4,194	100	591	611	1,032	1,421	1,509
Legal capital reserve	1,143	1,474	1,479	1,940	4,097	3,372	3,864	9,917	10,337	10,726	10,815
Retained earnings	-1,495	-2,014	-2,806	-3,594	-4,818	-904	-1,760	-9,077	-10,078	-10,613	-11,287
Evaluation/conversion difference				-0	3	2	1	-21	202		
Subscription rights to shares		21	21	21	23	32	34	57	116	184	195
Total liabilities and net assets	922	1,886	1,146	1,694	3,706	3,025	3,151	3,592	3,933	3,503	3,894
[Statements of cash flows]											
Cash flow from operating activities	-304	-729	-970	-607	-1,759	-438	-860	-1,325	-1,267	-1,169	-1,421
Loss before income taxes	-373	-517	-790	-785	-1,222	-902	-854	-7,314	-999	-533	-656
Cash flow from investing activities	-0	-1	-49	-121	-149	-50	-0	-137	-22	526	-28
Purchase of investment securities			-49	-116	-149			-100			-50
Cash flow from financing activities	907	1,454	9	946	3,471		978	1,221	718	369	1,356
Proceeds from issuance of common shares	917	234	9	486	3,932		973	40	138	369	34
Net increase in cash and cash equiv.	601	722	-1,010	217	1,562	-488	118	-240	-571	-273	-93
Cash and cash equiv. at beginning of period	285	887	1,610	599	817	2,379	1,891	2,009	2,032	1,461	1,160
Cash and cash equiv. at end of period	887	1,610	599	817	2,379	1,891	2,009	2,032	1,461	1,187	1,067
FCF	-305	-732	-1,021	-729	-1,909	-488	-860	-1,462	-1,289	-643	-1,450

Note: Consolidated basis until FY2021; non-consolidated basis from FY2022.

Source: Omega Investment from company materials



General disclaimer and copyright

This report was created and displayed based on interviews with the company concerned and financial statements, but we do not guarantee the accuracy, completeness, or credibility of the content and data. This report is for informational purposes only and is not intended to solicit or recommend investment. Omega Investment is not responsible for the consequences of using this report.

This report is informed by the target company through interviews with the target company, but the hypotheses, conclusions and all other content contained in this report are based on research by Omega Investment.

Intellectual ownership, including copyrights of the text and data, belongs to Omega Investment. Distribution, transfer, reproduction, transfer or other use constitutes copyright infringement of this report and is strictly prohibited.